These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 20593612)

  • 1. U.S. "way behind" on clozapine's benefits.
    Glazer WM
    Behav Healthc; 2010 May; 30(5):41-2. PubMed ID: 20593612
    [No Abstract]   [Full Text] [Related]  

  • 2. A systematic review of the evidence of clozapine's anti-aggressive effects.
    Frogley C; Taylor D; Dickens G; Picchioni M
    Int J Neuropsychopharmacol; 2012 Oct; 15(9):1351-71. PubMed ID: 22339930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dopamine D4-receptor variants, schizophrenia and clozapine therapy].
    Ewald HL; Mors NP; Rosenberg R
    Ugeskr Laeger; 1996 Jun; 158(25):3601-3. PubMed ID: 8693618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothesis testing: is clozapine's superior efficacy dependent on moderate D2 receptor occupancy?
    Carpenter WT; Zito JM; Vitrai J; Volavka J
    Biol Psychiatry; 1998 Jan; 43(2):79-83. PubMed ID: 9474440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing treatment with clozapine.
    Conley RR
    J Clin Psychiatry; 1998; 59 Suppl 3():44-8. PubMed ID: 9541338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A historical perspective of clozapine.
    Hippius H
    J Clin Psychiatry; 1999; 60 Suppl 12():22-3. PubMed ID: 10372606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the pharmacotherapy of schizophrenia.
    Borison RL
    Harv Rev Psychiatry; 1997; 4(5):255-71. PubMed ID: 9385002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of dopamine D2 receptors in the CNS inhibits sympathetic cutaneous vasomotor alerting responses (SCVARs), contributing to clozapine's SCVAR-inhibiting action.
    Blessing WW; Ootsuka Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):328-36. PubMed ID: 17055139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clozapine: a novel antipsychotic with a controversial introduction.
    Ogle MR; Miller MJ
    Indiana Med; 1991 Sep; 84(9):606-10. PubMed ID: 1682361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clozapine, cytokines, fever and sleep].
    Hinze-Selch D; Mullington J; Pollmächer T
    Wien Med Wochenschr; 1996; 146(13-14):311-3. PubMed ID: 9012164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis.
    Small JG; Milstein V; Marhenke JD; Hall DD; Kellams JJ
    J Clin Psychiatry; 1987 Jul; 48(7):263-7. PubMed ID: 2885310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine's cost-benefits.
    Hosp Community Psychiatry; 1991 Jan; 42(1):92-4. PubMed ID: 1902817
    [No Abstract]   [Full Text] [Related]  

  • 13. Overcoming clozapine's adverse events: a narrative review of systematic reviews and meta-analyses.
    Tanzer T; Pham B; Warren N; Barras M; Kisely S; Siskind D
    Expert Opin Drug Saf; 2024 Jul; 23(7):811-831. PubMed ID: 38814794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General pharmacology of clozapine.
    Coward DM
    Br J Psychiatry Suppl; 1992 May; (17):5-11. PubMed ID: 1358127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clozapine: a hypothesised mechanism for its unique clinical profile.
    Bunney BS
    Br J Psychiatry Suppl; 1992 May; (17):17-21. PubMed ID: 1418885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients.
    Miljevic C; Nikolic M; Nikolic-Kokic A; Jones DR; Niketic V; Lecic-Tosevski D; Spasic MB
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):303-7. PubMed ID: 19962416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ["Rather overweight and mentally present...". Patients evaluate clozapine].
    Boitz K; Angermeyer MC; Löffler W; Müller P; Priebe S
    Psychiatr Prax; 1999 Jul; 26(4):188-93. PubMed ID: 10457971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy.
    Breier A
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():122-5. PubMed ID: 7961555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
    Wheeler AJ
    Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormally persistent latent inhibition induced by lesions to the nucleus accumbens core, basolateral amygdala and orbitofrontal cortex is reversed by clozapine but not by haloperidol.
    Schiller D; Zuckerman L; Weiner I
    J Psychiatr Res; 2006 Mar; 40(2):167-77. PubMed ID: 15882871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.